Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders
Open accessThe DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index; 28 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and the underlying causative pathology. Blood glial fibrillary acidic protein (GFAP) has garnered attention as a FTD biomarker. However, investigations of GFAP in FTD have been hampered by symptomatic and histopathologic heterogeneity and small cohort sizes contributing to inconsistent findings. Therefore, we evaluated plasma GFAP as a FTD biomarker and compared its performance to that of neurofilament light (NfL) protein, a leading FTD biomarker. METHODS: We availed ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study resources to conduct a comprehensive cross-sectional and longitudinal examination of the susceptibility/risk, prognostic, and predictive performance of GFAP and NfL in the largest series of well-characterized presymptomatic FTD mutation carriers and participants with sporadic or familial FTD syndromes. Utilizing single molecule array technology, we measured GFAP and NfL in plasma from 161 controls, 127 presymptomatic mutation carriers, 702 participants with a FTD syndrome, and 67 participants with mild behavioral and/or cognitive changes. We used multivariable linear regression and Cox proportional hazard models adjusted for co-variates to examine the biomarker utility of baseline GFAP and NfL concentrations or their rates of change. RESULTS: Compared to controls, GFAP and NfL were elevated in each FTD syndrome but GFAP, unlike NfL, poorly discriminated controls from participants with mild symptoms. Similarly, both baseline GFAP and NfL were higher in presymptomatic mutation carriers who later phenoconverted, but NfL better distinguished non-converters from phenoconverters. We additionally observed that GFAP and NfL were associated with disease severity indicators and survival, but NfL far outperformed GFAP. Nevertheless, we validated findings that the GFAP/NfL ratio may discriminate frontotemporal lobar degeneration with tau versus TDP-43 pathology. CONCLUSIONS: Our head-to-head comparison of plasma GFAP and NfL as biomarkers for FTD indicate that NfL consistently outmatched GFAP as a prognostic and predictive biomarker for participants with a FTD syndrome, and as a susceptibility/risk biomarker for people at genetic risk of FTD. Our findings underscore the need to include leading biomarkers in investigations evaluating new biomarkers if the field is to fully ascertain their performance and clinical value.
Overview
CoChat Summary
## TL;DR
In this ALLFTD study of 1,057 participants, plasma NfL consistently outperformed plasma GFAP across FTD spectrum disorders as a diagnostic, prognostic, and susceptibility/risk biomarker. GFAP was elevated in FTD but generally had poor discriminatory power, while the GFAP/NfL ratio had some value for distinguishing FTLD-tau from FTLD-TDP, largely driven by NfL.
## Key findings
- In 1,057 participants (161 controls, 127 presymptomatic mutation carriers, 308 bvFTD, 76 nfvPPA, 83 svPPA, 92 CBS, 143 PSP-RS, 67 MBCI), both GFAP and NfL were elevated in FTD spectrum disorders, but NfL was consistently stronger.
- Baseline GFAP showed poor to moderate discrimination of controls from symptomatic groups, with age/sex-adjusted AUCs of 0.53 for MBCI and 0.56–0.68 for other symptomatic groups; NfL showed better discrimination, with AUCs of 0.69 for MBCI and 0.78–0.87 for other symptomatic groups.
- In presymptomatic mutation carriers, both biomarkers were higher in phenoconverters, but NfL better separated phenoconverters from non-converters: baseline AUC 0.77 vs 0.61 for GFAP, and rate-of-change AUC 0.78 vs 0.65.
- Higher GFAP and NfL were associated with worse disease severity and shorter survival after symptom onset, but NfL was stronger: for death after symptom onset, HRs were 2.97 for NfL vs 2.01 for GFAP in bvFTD, and 2.39 vs 1.36 in all FTD syndromes combined.
- For pathology classification, GFAP alone had little value (AUC 0.55 for FTLD-tau vs FTLD-TDP), while NfL and the GFAP/NfL ratio discriminated better (AUCs 0.78 and 0.73), with the paper stating this was largely driven by NfL.
## Methods
- Cross-sectional and longitudinal analysis using ALLFTD resources, including clinically normal mutation-negative controls, presymptomatic mutation carriers, symptomatic FTD spectrum groups, and an MBCI comparison group.
- Plasma GFAP and NfL were measured by single molecule array (Quanterix); the paper reports baseline and longitudinal measures across 1,691 samples from the 1,057 participants.
- Main analyses used multivariable linear regression, Cox proportional hazards models, Spearman correlations, and AUC-based discrimination analyses, with Bonferroni correction and sensitivity analyses using GEE/marginal models and BMI adjustment.
## Limitations
- The authors state that participants “may not represent the general FTD population,” and diagnoses were clinical rather than neuropathologic for most participants.
- The paper states BMI was missing for 18% of participants, so it was not included in primary multivariable models; this is an evident limitation because BMI can confound biomarker levels.
- The authors note medication/supplement use was not accounted for, and give minocycline as a possible confounder of NfL.
- The paper also notes some phenotype groups were small, which raises the possibility of false-negative findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
11 Valid · 0 Not valid · 3 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Indeed, some studies reported elevated blood GFAP in participants with FTD compared to controls [8–18] but others observed no such GFAP increase in FTD [19–22].”
§ Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders > Background
What the sources say
- Supportedcites [8] Zhu N, Santos-Santos M, Illan-Gala I, Montal V, Estelles T, Barroeta I, Altuna M, Arranz J, Munoz L, Belbin O, et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener. 2021;10(1):50. source
The Results section ('Plasma GFAP and NfL concentrations differ between FTD and AD'; page unavailable) reports significantly higher plasma GFAP in participants with FTD than in cognitively normal controls. This directly supports the cited claim about elevated blood GFAP in FTD. (LLM, conf=0.95)
- Supportedcites [9] Heller C, Chan E, Foiani MS, Todd E, Russell LL, Greaves CV, Heslegrave AJ, Warren JD, Zetterberg H, Bocchetta M, et al. Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2020. source
The Introduction identifies semantic variant primary progressive aphasia (svPPA) as a subtype of FTD. The Results report significantly higher plasma GFAP in participants with svPPA than in controls (p=0.006), directly supporting this study as an example of the cited finding. (LLM, conf=0.94)
- Supportedcites [10] Marelli C, Hourregue C, Gutierrez LA, Paquet C, Menjot De Champfleur N, De Verbizier D, Jacob M, Dubois J, Maleska AM, Hirtz C, et al. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. J Alzheimers Dis. 2020;74(3):903–11. source
Our copy reports elevated blood (plasma) GFAP in bvFTD versus controls: the Abstract (p. 4) states 'Plasma glial fibrillary acid protein (GFAP) was strongly increased in both bvFTD groups compared with the values in controls of the same age', and the Results (Brain imaging/plasma data, p. 7) report plasma GFAP significantly higher in presenile and late-onset bvFTD than in age-matched healthy controls (Table 4). The Discussion (p. 8) repeats the strong GFAP increase in both bvFTD groups. This is one of the studies supporting the citing sentence's claim that some studies found elevated blood GFAP in FTD relative to controls (bvFTD being the FTD variant examined here). (LLM, conf=0.90)
- Supportedcites [11] Benussi A, Ashton NJ, Karikari TK, Gazzina S, Premi E, Benussi L, Ghidoni R, Rodriguez JL, Emersic A, Binetti G, et al. Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2020;77(3):1129–41. source
The Results section, ‘Serum GFAP concentrations in FTLD subgroups,’ reports significantly higher serum GFAP in several FTD subgroups than in healthy controls. The Discussion likewise says the study confirmed increased serum GFAP in behavioural and language variants of FTD. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Katisko K, Cajanus A, Huber N, Jaaskelainen O, Kokkola T, Karkkainen V, Rostalski H, Hartikainen P, Koivisto AM, Hannonen S, et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021;92(12):1305–12. source
- Could not verifycites [13] Sarto J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, Falgas N, Esteller D, Contador J, Fernandez G, Gonzalez Y, Tort-Merino A, et al. Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic Cohort. Neurology. 2023;100(8):e860–73. sourceExperimental — accuracy not yet measured
Our copy of Sarto et al. (Neurology 2023) reports GFAP group differences only for AD: 'GFAP concentrations were different between groups... and were higher in AD compared with CU, SND, and LBD. GFAP levels were similar in AD and Aβ+ LBD or FTD' (Results), and the FTD-versus-control separation is attributed to NfL ('increased the most in patients with FTD'; Results, Clinical Scenario 2). The Discussion likewise describes plasma GFAP as rising 'throughout the AD continuum and in Lewy body dementia' while reserving the FTD elevation for NfL. No passage in our copy states that GFAP was elevated in FTD compared with controls (searched: GFAP in FTD vs cognitively unimpaired controls; plasma GFAP frontotemporal dementia elevation; astrocytic marker GFAP FTD previous studies), so this source cannot be checked as one of the studies reporting that finding. (LLM, conf=0.62)
- Partly supportedcites [14] Benussi A, Cantoni V, Rivolta J, Archetti S, Micheli A, Ashton N, Zetterberg H, Blennow K, Borroni B. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration. Alzheimers Res Ther. 2022;14(1):155. sourceExperimental — accuracy not yet measured
The Results (Participant characteristics) report significantly increased GFAP in the pooled FTLD group compared with healthy controls. The Participants section shows that this group included people with bvFTD alongside other FTLD-spectrum syndromes; the passage does not establish a GFAP increase for participants with FTD separately. (LLM, conf=0.84)
- Supportedcites [15] Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L, Pantieri R, Polischi B, Romano L, Suffritti M, et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14(1):153. source
The Results section reports that healthy controls had lower plasma GFAP than every diagnostic group, including FTD (p < 0.001). The Discussion also states that plasma GFAP was higher in all disease groups than in controls. (LLM, conf=0.94)
- Supportedcites [16] Bolsewig K, Hok AHYS, Sepe FN, Boonkamp L, Jacobs D, Bellomo G, Paoletti FP, Vanmechelen E, Teunissen CE, Parnetti L, et al. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. J Alzheimers Dis. 2022;90(1):363–80. source
The Results report significantly higher serum GFAP in participants with FTD than in the OND group (p < 0.05). The Study population section explicitly identifies the cognitively unimpaired OND participants as controls, although they had minor neurological conditions. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [17] Chen Y, Wang Y, Tao Q, Lu P, Meng F, Zhuang L, Qiao S, Zhang Y, Luo B, Liu Y, et al. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study. Clin Chim Acta. 2024;558:118784. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we found that NfL was elevated in presymptomatic mutation carriers prior to phenoconversion and in participants with FTD, and it associated with indicators of disease severity [5].”
§ Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders > Background
What the sources say
- Supportedcites [5] Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, Bozoki AC, Dickerson BC, Domoto-Reilly K, Foroud T, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022;3(4):100607. source
The Results section reports that presymptomatic mutation carriers who later phenoconverted had higher baseline plasma NfL than controls and carriers who remained asymptomatic. Baseline measurements preceded phenoconversion by a median of 1.3 years. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some FTD syndromes strongly associate with FTLD-tau (i.e., PSP-RS) or FTLD-TDP (i.e., FTD-ALS) [4], but bvFTD is just as likely to be caused by either proteinopathy (with a small percentage of cases caused by rarer FTLD pathologies).”
§ Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders > Background
What the sources say
- Supportedcites [4] Bahia VS, Takada LT, Deramecourt V. Neuropathology of frontotemporal lobar degeneration: a review. Dement Neuropsychol. 2013;7(1):19–26. source
The Introduction reports that bvFTD is associated with FTLD-TDP in around 50% of cases and FTLD-tau in 40%, with the remainder mostly FTLD-FUS. Those proportions support the claim that the two proteinopathies are roughly comparably likely, with a smaller share due to other pathology. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we found that NfL was elevated in presymptomatic mutation carriers prior to phenoconversion and in participants with FTD, and it associated with indicators of disease severity [5].”
§ Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders > Background
What the sources say
- Supportedcites [5] Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, Bozoki AC, Dickerson BC, Domoto-Reilly K, Foroud T, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022;3(4):100607. source
The Results section is titled “Plasma NfL is elevated in FTD,” and the Discussion states that plasma NfL was elevated even in FTD patients with mild symptoms. Page numbers were not provided in the passages. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we found that NfL was elevated in presymptomatic mutation carriers prior to phenoconversion and in participants with FTD, and it associated with indicators of disease severity [5].”
§ Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders > Background
What the sources say
- Supportedcites [5] Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, Bozoki AC, Dickerson BC, Domoto-Reilly K, Foroud T, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022;3(4):100607. source
The Results section, “Plasma NfL correlates with indicators of disease severity,” reports that higher plasma NfL was associated with worse performance on all assessed tests for the combined FTD group and for bvFTD alone. It also reports associations with selected indicators in other FTD syndromes. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
62 more claims · 2 with their cited sources checked
Create a free account to see all 131 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 46
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674 · cited 1×
“Therefore, in secondary analyses, aforementioned regression analyses were redone using either generalized estimating equations (GEE) (for linear regression models) [36], or using a marginal models approach (for Cox regression models) [37] to account for familial relatedness.”
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 1×
“All diagnoses were made clinically using widely accepted published criteria for each disorder [25, 26].”
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“All diagnoses were made clinically using widely accepted published criteria for each disorder [25, 26].”
Self-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609 · cited 2×
“…with ALS or FTLD-TDP type B were included in the Irwin study [42], they were excluded from our study given that TDP-43 type B is associated with FTD-ALS phenotypes [35], and participants with ALS have significantly higher plasma NfL than participants with FTD, which may confound our analyses [5].”
GOLLAN, T. H., WEISSBERGER, G. H., RUNNQVIST, E., MONTOYA, R. I., & CERA, C. M. (2012) · Bilingualism: Language and Cognition · doi:10.1017/s1366728911000332 · Cited by 527 · cited 1×
“The total score includes items named correctly with semantic, but not phonemic, cues [32].”
The Use of the Rank Transform in Regression
Iman, R. L., & Conover, W. J. (1979) · Technometrics · doi:10.1080/00401706.1979.10489820 · Cited by 514 · cited 1×
“Due to the combination of: 1) skewness and presence of outliers in rates of GFAP and NfL change per year, and 2) small sample sizes, we utilized a rank transformation of rates of change per year in GFAP and NfL concentrations in all regression analyses to minimize outlier impact on the results [34].”
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Cited by
Daponte, A., Koros, C., Skarlis, C., Siozios, D., Rentzos, M., Papageorgiou, S. G., & Anagnostouli, M. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199739 · Cited by 42
“GFAP and NfL were associated with disease severity indicators and survival, but NfL far outperformed GFAP [144].”
Chu, M., Yue, A., Yan, S., Yu, B., He, Q., Chen, Y., Hou, J., Nan, H., Ye, H., Nie, B., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70561 · Cited by 13
“36 Plasma vascular marker VCAM1 is primarily associated with WMH, implicating BBB disruption contributing to white matter damage in bvFTD.”
Davydow, D. S., Brasfield, M., Morrow, C. B., Staffaroni, A. M., Pontone, G. M., & Asken, B. M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2429 · Cited by 9
Kivisäkk, P., Fatima, H. A., Wu, C., Padmanabhan, N., Romero, D., Gorham, T., Weik, M., Dodge, H. H., Scherzer, C. R., Das, S., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214351 · Cited by 13
Sheth, U., Harrison, R., Ferber, K. L., Rosenbaugh, E. G., Bevis, A., Khillan, R., Benatar, M. G., Bjorklund, N. L., Daniel, E., Harris, G. A., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0610 · Cited by 10
“…NfL has demonstrated prognostic utility for amyotrophic lateral sclerosis (ALS) [4], coronavirus disease 2019 [5], frontotemporal dementia (FTD) [6, 7], Parkinson ’ s disease [8], stroke [9], multiple sclerosis (MS) [10] and many other neurological diseases [3, 11]; nonetheless, it must be…”
Self-citation
Metadata
- Authors
- Sheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., Ramos, E. M., Appleby, B. S., Bozoki, A. C., Darby, R. R., Dickerson, B. C., Domoto-Reilly, K., Galasko, D. R., Ghoshal, N., Graff-Radford, N. R., Grant, I. M., Hales, C. M., Hsiung, G.-Y. R., Huey, E. D., Irwin, D., Kwan, J. Y., Litvan, I., Mackenzie, I. R., Masdeu, J. C., Mendez, M. F., Onyike, C. U., Pascual, B., Pressman, P. S., Roberson, E. D., Snyder, A., Tartaglia, M. C., Seeley, W. W., Dickson, D. W., Rosen, H. J., Boeve, B. F., Boxer, A. L., Petrucelli, L., & Gendron, T. F.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Harvard University (US)
- University of California System (US)
- Washington University in St. Louis (US)
- Northwestern University (US)
- Emory University (US)
- University of British Columbia (CA)
- Brown University (US)
- University of Pennsylvania (US)
- National Institutes of Health (US)
- Houston Methodist (US)
- Johns Hopkins University (US)
- Oregon Health & Science University (US)
- University of Alabama at Birmingham (US)
- University of Toronto (CA)
- Corresponding author
- Gendron, Tania F.
- ORCID
- Sheth, Udit
- Öijerstedt, Linn
- Heckman, Michael G.
- White, Launia J.
- Heuer, Hilary W.
- Forsberg, Leah K.
- Faber, Kelley M.
- Foroud, Tatiana M.
- Rademakers, Rosa
- Ramos, Eliana Marisa
- Appleby, Brian S.
- Bozoki, Andrea C.
- Darby, R. Ryan
- Dickerson, Bradford C.
- Galasko, Douglas R.
- Ghoshal, Nupur
- Grant, Ian M.
- Hales, Chadwick M.
- Hsiung, Ging-Yuek Robin
- Huey, Edward D.
- Irwin, David
- Kwan, Justin Y.
- Litvan, Irene
- Mackenzie, Ian R.
- Masdeu, Joseph C.
- Mendez, Mario F.
- Onyike, Chiadi U.
- Pressman, Peter S.
- Roberson, Erik D.
- Snyder, Allison
- Tartaglia, M. Carmela
- Seeley, William W.
- Dickson, Dennis W.
- Rosen, Howard J.
- Boeve, Bradley F.
- Boxer, Adam L.
- Petrucelli, Leonard
- Gendron, Tania F.
- Venue
- Molecular Neurodegeneration
- Published
- 2025-03-12
- Volume
- 20
- Issue
- 1
- Pages
- 30-30
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC11905702
- OpenAlex
- W4408362064
- Cited by
- 20
- References
- 75
- Citations by year
- 2026: 8 · 2025: 12
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging (U19AG063911, U01AG045390, U24AG021886, P30AG062677, P01AG019724, K24AG045333, P30AG066509)
- National Institute of Neurological Disorders and Stroke (U54NS092089, R35NS097273, P01NS084974, P01NS099114)
- Association for Frontotemporal Degeneration
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal dementia, frontotemporal lobar degeneration, glial fibrillary acidic protein, neurofilament light chain, plasma biomarkers, presymptomatic mutation carriers, phenoconversion, tau pathology, TDP-43 pathology, disease progression, survival, prognostic factors, biomarkers of susceptibility, single molecule array, longitudinal biomarker changes
- MeSH terms
- Adult, Aged, Cross-Sectional Studies, Female, Glial Fibrillary Acidic Protein, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers, Neurofilament Proteins, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders. https://app.cochat.ai/papers/10.1186/s13024-025-00821-4
- The paper
- Sheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., Ramos, E. M., Appleby, B. S., Bozoki, A. C., Darby, R. R., Dickerson, B. C., Domoto-Reilly, K., Galasko, D. R., Ghoshal, N., Graff-Radford, N. R., . . . Gendron, T. F. (2025). Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-025-00821-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.